1. Germany Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Sangui Biotech International, Inc.

Sangui Biotech International, Inc.

SGBI
Sangui Biotech International, Inc.US flagOther OTC
0.00
USD
- -
- -
41,980.00Market Cap
2010 Y
2011 Y
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-0.01
-0.02
-0.03
-0.02
-0.01
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
-0.01
-0.01
-0.01
-0.01
-0.01
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-0.35
-0.3
-0.03
-0.26
-0.26
-0.25
-0.24
-0.02
-0.02
-0.02
-0.02
-0.02
-0.02
-0.02
Tangible Book Value per Share
- -
- -
0.01
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
76
94
117
129
137
146
155
178
188
197
202
204
209
210
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
-5,795.79
-31,361.91
-24,822.02
-1,179.24
-986.95
-590.21
-751.74
-468.27
-269.66
-383.67
-627.34
-230.45
-201.54
-141.36
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-1
-2
-3
-2
-1
-1
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-5,411.84
-27,456.73
-23,358.78
-1,986.5
-1,070.48
-552.84
-879.57
-456.71
-261.57
-367.7
-666.58
-303.26
-85.72
-154.23
Working Capital
- -
- -
1
- -
- -
- -
- -
- -
- -
-1
-1
-1
-1
-1
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
- -
- -
1
- -
- -
- -
- -
- -
- -
-1
-1
-1
-1
-1
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-0.4
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Sep'23
Dec'23
Mar'23
ST Debt
1
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
210
210
210
Market Capitalization
2
1
1

Working Capital

FRC

•

in mil. unless spec.
Sep'23
Dec'23
Mar'23
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
1
1
1
Payables & Accruals
- -
- -
- -
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-481.04%
29.77%
2.24%
Free Cash Flow
-12.78%
-12.22%
-3.7%
Net Income, GAAP
-27.12%
-16.35%
-70.18%
Sales/Revenue/Turnover
69.95%
18.66%
5.5%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Thomas Striepe
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Address
BleichenbrUecke 9 Hamburg Germany 20354
IPO Date
Mar 27, 1997
CIK
0001104280
Website
sanguibiotech.com
Similar Companies
CLS Holdings USA, Inc. (CLSH)
Gnomestar Craft Inc. (VDQSF)
Bhang Inc. (BHNGF)
Isracann Biosciences Inc. (IPOT.CN)
China National Medicines Corporation Ltd. (600511.SS)
China Resources Double-Crane Pharmaceutical Co.,Ltd. (600062.SS)
Business
Sangui Biotech International, Inc. (SGBI) is a holding company that develops, manufactures and commercializes pharmaceutical, medical and cosmetic products focused on hemoglobin-based artificial oxygen carriers and oxygen transport solutions through its 90%-owned German subsidiary SanguiBioTech GmbH; core products include Granulox, a hemoglobin spray for chronic wound healing licensed to Molnlycke Health Care and sold globally including Southeast Asia, Hemospray hemoglobin wound spray, Chitoskin wound pads, nano-formulations for skin regeneration in gels and emulsions, and oxygen carriers for blood additives, volume substitutes and topical therapies addressing arterial occlusion, anemia, blood loss from surgery or trauma, and skin rejuvenation. The company operates primarily in Europe with worldwide partnerships for product distribution and reported fiscal year 2025 revenues of USD 375,787 from royalty income and product sales, reflecting an 182% increase driven by higher Granulox sales alongside a positive operating result of USD 215,951 and annual net gain of USD 69,312 despite elevated exchange rate losses. Founded in 1995 and headquartered in Hamburg, Germany, Sangui Biotech targets healthcare providers, wound care specialists and cosmetic markets with ongoing emphasis on CE certification for pipeline products like SBT 102 for septic shock treatment.